INTRODUCTION

BDG LifeSciences' Research Project Training Program is a one-of-a-kind initiative designed to strengthen your profile and enhance career opportunities, whether for jobs or higher studies, by offering the chance to work on novel research projects using the latest technologies in bioinformatics. Since 2010, this program has addressed the critical need for high-quality publications by combining innovative teaching methods with practical applications. Conducted entirely online, it provides participants with the flexibility to choose session timings while saving on travel, accommodation, and food expenses. With over 88 research projects successfully completed and published at the international level, this program is ideal as a major or thesis project for final-year students or for those looking to advance their profiles.

Applications WILL soon open for 5 SEATS in our 93 novel research project

---

Introduction of the Project

The future of precision oncology lies at the intersection of CRISPR genome engineering, single-cell transcriptomics, and systems-level regulatory modeling. At BDG Lifesciences, we are preparing to launch a long-term, research-intensive CRISPR project designed for highly motivated students, researchers, and early-career scientists who aspire to work at the frontiers of cancer immunotherapy and functional genomics.

This upcoming project is not a short course or a superficial training module. It is a deep, publication-oriented research experience, structured to mirror how cutting-edge CRISPR studies are conceived, executed, validated, and communicated in top-tier journals.

---

Why This Project Matters

Most CRISPR studies still rely on bulk readouts and oversimplified interpretations of gene function. However, tumour ecosystems are inherently heterogeneous, shaped by complex cellular interactions and dynamic regulatory rewiring.

Our forthcoming CRISPR research project focuses on:

• CRISPR-Cas9 perturbations mapped at single-cell resolution

• Decoding gene regulatory network (GRN) rewiring inside the tumour microenvironment (TME)

• Understanding how immune and cancer cell states shift in response to targeted genetic disruptions

• Moving beyond differential expression toward mechanistic, systems-level insight

Participants will engage with real-world datasets and workflows that reflect how modern cancer immunogenomics research is performed in leading academic and translational labs.

---

Scientific Scope & Research Vision

This project is embedded within the broader theme of Integrated Computational Immunogenomics and RNA-Centric Therapeutics, with a strong emphasis on cancer immunotherapy.

Core research elements include:

• Single-cell RNA-seq analysis of tumour microenvironments

• CRISPR perturbation profiling and editing outcome analysis

• Regulatory network inference to identify causal gene programs

• Functional enrichment and biological interpretation aligned with immuno-oncology

• Research storytelling and manuscript-ready outputs

Rather than following a “tool-centric” approach, the project is designed around scientific questions, hypothesis-driven workflows, and research reproducibility—the hallmarks of impactful publications..

---

Project Structure (Preview)

The project will unfold in carefully designed phases, spanning approximately 12–18 months, allowing participants to experience the full lifecycle of a serious research study:

• Data acquisition and preprocessing

• CRISPR perturbation modeling and regulatory inference

• Biological validation and enrichment analysis

• Scientific writing, visualization, and manuscript preparation

Participants will gain hands-on experience using widely accepted, open-source research tools commonly cited in Nature, Cell, and ACS publications, ensuring both academic credibility and practical relevance.

---

Who Should Watch This Space

This project is being designed for individuals who:

• Aspire to pursue PhD-level or publication-driven research

• Want to build strong computational biology and CRISPR expertise

• Are interested in cancer immunotherapy, functional genomics, or systems biology

• Seek mentorship and research exposure aligned with global research standards

Admission will be selective, and the project will not be run frequently.

---

What Are the Benefits of This Program?

• Hands-on training with globally used open-source tools.
• Guidance from experts in bioinformatics and drug discovery.
• Enhanced knowledge of RNA structure and druggability.
• Boost your academic and professional credentials with a unique, future-ready skillset.

---

Launch Status

🚧 Currently in pre-launch phase
📅 Expected launch: End of February 2026
📌 Registrations will open after the launch

We encourage interested candidates to bookmark this page and follow BDG Lifesciences updates. Early access details, eligibility criteria, and registration timelines will be announced shortly

---

At BDG Lifesciences, we don’t just teach tools.

We train minds to think like scientists—and to publish like one.

Stay tuned. The next chapter in CRISPR-driven cancer research is about to begin

TEAM FOR CURRENT/ONGOING RESEARCH PROJECTS

92. Mapping Druggable RNA Landscapes: An End-to-End Pipeline from Transcriptomics to Therapeutic Targeting

1. Yana Joshi, Henry M. Jackson High School, WA, USA. 
2. Sharvari Kulkarni, Chief Technical Officer, BDG Lifesciences, India.
3. Ayanjeet Chowdhury, Technical Officer, BDG Lifesciences, India.

91. ImmunoSpatial Blueprint: Mapping Tumor-Immune Interactions in Triple-Negative Breast Cancer Using Spatial Transcriptomics

1. Dr Malu Sreekumar, Jawaharlal Institute of Post-graduate Medical Education and Research (JIPMER), Puducherry, India. 
2. Tanmay Bandbe, Guru Nanak Khalsa College of Arts, Science & Commerce, Mumbai, India.

90. Single-cell RNA-seq Analysis of Chemotherapy-Induced Transcriptomic Changes in Pancreatic Ductal Adenocarcinoma (PDAC)

1. Dr Ilham Mahgoub, Qatar University, Qatar.
2. Ritam Baruah, Ajanta Pharma Limited, Assam, Indi.
3. Aakash Deva Thirukonda Prakash, KTH Royal Institute of Technology, India.

88. Computational Insights into Selective ERβ Agonists for Benign Prostatic Hyperplasia (BPH) Treatment | A Virtual Screening, Molecular Docking & Simulations Study.

1. Shivani Tuli, University of Pittsburg, Pittsburgh, USA.
2. Rakshitha Prakash, Vellore Institute of Technology (VIT), India.
3. Chandrima Das Sinha, Techno India University, India.
4. Swapnaja Gulawani, Agharkar Research Institute, India.
5. Trần Thị Thư, Hồ Chí Minh, Vietnam.

87. Decoding Pan-Cancer Pathogenesis: A Multi-Layered Analysis of Prognostic mRNAs, miRNAs, lncRNAs via Co-Expression Networks and PPINs

1. Ritam Baruah, Ajanta Pharma Limited, Assam, India.
2. Tanmay Bandbe, Guru Nanak Khalsa College of Arts, Science & Commerce, Mumbai, India

86. Unveiling Autoimmune Genes and Regulatory Elements in Head and Neck Squamous Cell Carcinoma through Advanced Machine Learning and Network-Based Analysis

1. Mathews Kennedy, Trivandrum, Kerala, India.
2. Angela Susan Anil, School of Biotechnology, Amrita Vishwa Vidyapeetham, Kerala. 
3. Elham O Mahgoub, Alneelain University, Sudan.

85. Molecular Modeling study of derivatives of Leaf Extracts of medicinal plant Solanum torvum and Serine/Threonine Kinase from Mycobacterium Tuberculosis

1. Tenzin Kalsang, Manipal Academy of Higher Education, India.
2. Elham O Mahgoub, Alneelain University, Sudan.
3. Laxmi C M, Teesside University, Middlesbrough, UK.
4. Ilham Said Salman, Beirut Arab University, Lebanon.

84. Targeting Tumor Progression: Identifying Differentially Expressed Genes and Pathways in Pancreatic Ductal Adenocarcinoma using RNAseq

1. Kasturi Mukherjee, Kyvor Genomics Pvt. Ltd , Chennai, India.

83. Next Generation Sequencing | Unraveling the Cancer Code: Gene Expression Profiling with RNAseq

1. Ilham Omer Mahgoub, Alneelain University, Sudan
2. Arnav Kolluru,Liberty High School, Renton, WA, United States.

82. NGS Data Analysis | Prediction of Multiple Myeloma Using RNASeq Data

1. Dolly Jagwani, Indian Institute of Science Education and Research, Pune (IISER-P), Maharashtra, India
2. Mathews Kennedy, Cancer Biology and Therapeutics, Middlesex University, London, UK.

81. NGS Data Analysis of Cancer Tissues | A Cancer Biology Study

1. Pooja Prakash Mankar, - Shri Shivaji College of Arts, Commerce and Science, Akola, India. 
2. Amit Kumar, ICMR, New Delhi, India.
3. Ilham Omer Mahgoub, Alneelain University, Sudan.

79. Molecular Modeling study of Cyclophilin A and derivatives of Ganoderiol F (26,27-Dihydroxylanosta-7,9(11),24-trien-3-one): Design of novel inhibitors for CyclophilinA

1. Ilham Omer Mahgoub, Alneelain University, Sudan.
2. Sharda Sambhakar, Department of Pharmacy, Banasthali Vidyapith, Rajasthan, India.

78. Molecular Modeling study of derivates of Ethyl 2-[(4-chlorophenyl)carbamoylamino]-5-methyl-4-phenylthiophene-3-carboxylate and α-D-glucose-1-phosphate thymidylyltransferase (Mycobacterium-RmlA) | Discovery of new drugs for multidrug-resistant (MDR)Mtb

1. Jyotishikha, Department of Biotechnology, Amity University, India.
2. Harmanpreet Kaur, Red River College, Winnipeg, Manitoba, Canada.
3. Roma Sharma, Sorting Hat Technologies, India.
4. Yamini Saraswathi Chapala, Bhavans Vivekananda College, Hyderabad, India.

76. Molecular Modelling study of p53-MDM2 and derivatives of Ganoderiol F | Discovery of new Anti-CANCER Drugs by Molecular Docking & MD Simulations Approach

1. Rytis Boreika, Abbaltis, Sittingbourne, United Kingdom.
2. Divya M B, Department of Biochemistry, St Aloysius College, Mangalore, India.
3. Sujoy Chakraborty, Department of Biotechnology, Amity University, India.
4. Roshni Thapa, Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.

75. NGS Data Analysis on Alzheimer's

1. Raajesh Iyer B, Prophecy Technologies, San Diego, CA, USA.
2. Shourya Majumder, Department of Biotechnology, IIT Kharagpur, India.

74. NGS Data Analysis on Cancer Biology | Analyzing cancer tissues

1. Vikram Krishna B, Sri Sankara Arts and Science College (Autonomous), Kanchipuram, Tamilnadu, India.
2. Dexter Achu Mosoh, SAGE University Bhopal Campus, India.
3. Dr.Dheepa Manoharan, Infectious Diseases, Dubai, UAE

73. Inhibitory study of Focal Adhesion Kinase (FAK): A Virtual screening, Molecular Docking & ADMET study for  combating cancer

1. Rutupurna Satapathy, KIIT School of Biotechnology, Orissa, India.
2. Dexter Achu Mosoh, SAGE University Bhopal Campus, India.

72. Virtual Screening and Molecular Docking study of derivatives of chromen-2-one as selective Estrogen Receptor beta Agonists (SERBAs): Molecular Modeling study of Benign Prostatic Hyperplasia

1. Keerthi Renganathan, School of Biotechnology and Bioinformatics, D.Y. Patil University, India
2. Nikita Mundhara, Department of Biotechnology, Indian Institute of Technology Bombay, Mumbai, India.
3. Tanveen Kaur Soni, JIS University, Agarpara, Kolkata, India.
4. Sakshi Pandey, Banaras Hindu University, India.

71. Molecular Modeling Study of extracts of medicinal plants as potential anti-tubercular agents

1. Titiksha Sharma, Delhi Technological University, Delhi, India.
2. Jhancy Raj, Biogenix Research Centre, Thiruvananthapuram, Kerala, India.
3. Awadhesh Kumar Verma, Jawaharlal Nehru University, New Delhi, India.
4. Shaniya Ali, Mar Athanasios College for Advance Studies Thiruvalla, Thiruvalla, Kerala, India.

70. Virtual screening & Molecular Docking of DOT1L & derivatives of Pinometostat | Molecular Modeling study of Therapeutic Target in Mixed-lineage Leukemia (MLL)

1. Lakshmi Prasannah, Department of Pharmaceutical Sciences, Bengaluru, India.
2. Komal Kumari Gohil, K.J. Somaiya College of Science & Commerce, Mumbai,India.
3. Yannick Luther Agbana, Pan African University Life and Earth Sciences Institute, University of Ibadan, Nigeria.
4. Palak Shrivastava, Department of Biotechnology, Dr. Harisingh Gour University, Sagar, India.

69. Targeting the Wnt/β-catenin signaling pathway in cancer by molecular modeling study of Ganoderiol F and Beta- Catenin

1. Mithra M S, Rajiv Gandhi Centre for Biotechnology, India.
2. Nikhil K Gigi, The Institute of Science, Dr. Homi Bhabha State University, Mumbai.
3. Madhumita Ghosh, Ballygunge Science College, University of Calcutta, Kolkata, West Bengal, India
4. Raktim Chowdhury, University of Mumbai, India.
5. Zehratul Quresh, Metropolis Healthcare, Hyderabad, India.

68. Biomarker discovery based on omics technology

1. Bansari Modi, Department of Botany , Bioinformatics, Climate change and impact management, School of Science, Gujarat University, India.
2. Nishant Joshi, Shiva Nadar University, India.

67. Study of SARS-CoV-2 main protease (Mpro) and derivatives of Norterihanin to investigate potential inhibitors using Virtual Screening & Molecular Docking

1. Satabdi Mohanty, Department of Biotechnology & Genetic Engineering, SRM University, India.
2. Dhriti Gaur, Department of Biotechnology , Bennett University, India.
3. Aditya G Lavekar, PI Industries, Rajasthan, India.

66. Molecular Modelling study of SARS-CoV-2 spike protein of COVID-19 with derivatives of Saikosaponins | Examining the anticoronaviral activity of saikosaponins (A, B2, C and D)

1. Amisha Garg, System Biology and Bioinformatics, Panjab University, Chandigarh, India. 
2. Sweta Mohanty, Department of Biotechnology, KIIT University, India.
3. Rudra Prasad Nayak, Department of Biotechnology, KIIT University, India.
4. Suparna Giri, Department of Biotechnology, KIIT University, India.
5. Aakash Deva T.P, School of Bioengineering, SRMIST, Chennai, India.

65. Molecular Modeling study of Southeast Asian Medicinal Plant Aglaia erythrosperma  and α-D-glucose-1-phosphate thymidylyltransferase (Mycobacterium-RmlA) | Discovery of new drugs for multidrug-resistant (MDR) Mtb

1. Arka Sanyal, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India.
2. Ankita Mohanty, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
3. Saswat Dash, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
4. Aditi Rubal, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
5. Anusakha Panigrahi, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
6. Adrija Dihingia, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India

64.Molecular Modeling study of Cyclophilin A and derivatives of 1,8-Diamino-2,4,5,7-tetrachloroanthraquinone: Design of novel inhibitors for Cyclophilin A 

1. Safiya Aafreen, Biomedical Engineering, Johns Hopkins University , Baltimore, USA.
2. Jyothi Giridhar, Narayana Pharmacy College, JNTU Anantapur, India.
3. Sanica Nadkarni, MGM Institute of Health Sciences, India.
4. Ankita Saha, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee(IITR), Roorkee, Uttarakhand, India.
5. Nirav Parmar, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee(IITR), Roorkee, Uttarakhand, India.
6. Manjari Gaur, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee(IITR), Roorkee, Uttarakhand, India.

63. Molecular Modelling study of Catalytic domain of protein kinase PknB from Mycobacterium tuberculosis | Discovery of new Anti-Tubercular Drugs

1. P Ansuman Abhisek, MKCGMCH, Odisha, India.
2. Chitra Roy, Ballygunge Science College, University of Calcutta, Kolkata, India.
3. Ramya Vishwanathan, Biotechnology Engineering, SRM Institute Of Science And Technology, India.
4. Niyati Bisht, Department of Immunology and Virology, Amity University, Noida, India.
5. Mudita Appasaheb Kadam, Maulana Abul Kalam Azad University of Technology, Kolkata, West Bengal, India. 

62. Molecular Modelling study of p53-MDM2 | Discovery of new Anti-CANCER Drugs by Molecular Docking & MD Simulations Approach

1. Ngoc Pham, The Applied Chemistry Department of the International University, Ho Chi Minh, Vietnam.
2. Remya Prajeshgopal, Virology Department, Emirates Modern Poultry Co(Al Rawdah), Dubai, UAE.
3. Shibam Dey, B.Tech+ M. Tech Biotechnology Dual Degree, KIIT University Bhubaneshwar,Odhisa, India
4. Shalini Susmita, B.Tech+ M. Tech Biotechnology Dual Degree, KIIT University Bhubaneshwar,Odhisa, India.
5. Anurag Chatterjee, B.Tech+ M. Tech Biotechnology Dual Degree, KIIT University Bhubaneshwar,Odhisa, India.

61. Molecular modeling of sphingosine 1-phosphate receptor 1(S1P1) as target for multiple sclerosis | A Virtual screening, Molecular docking & ADMET study

1. Veera Raghava Choudary Palacharla, Scientist, Drug Discovery, M.Pharmacy, Annamalai University, India.
2. Dr Arul Amuthan, Division of Siddha, Center for Integrative Medicine and Research (CIMR), Manipal University, India.
3. Sandip Jaiswal, Operations manager (Cloud Platform), CSC, India.
4. Manika Gupta, Master of Science in Genomics, Amity Institute of Virology and Immunology, Amity University, India.
5. Dhanush R A, B. Tech - Genetic engineering, SRM Institute of Science and Technology, India.
6. Poonam Dhiman, BS-MS Integrated Course, Indian Institute of Science Education and Research, Mohali, India.
7. Preethi Varriar, Bachelor of Technology (B. Tech), Biotechnology, Delhi Technological University, India
8. Mohammad Khan, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India
9. Shagufta Khan, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India.

60. Inhibitory study of α-D-glucose-1-phosphate thymidylyltransferase (Mycobacterium-RmlA) | Discovery of new drugs for multidrug-resistant (MDR) Mtb

1. Prof. Dr. Ali Abdulhafidh Ibrahim Al-Shaikhli, Department of Mathematical and applied computer, College of Science, Al-Nahrain University, Jadriyah, Baghdad, Iraq.
2. Dr. Prince Prashant Sharma,Gurukula Kangri Vishwavidyalaya, Department of Pharmaceutical Sciences, Haridwar, India.
3. Gauri Kiran Vanjari, Bachelor of Dental Surgery, SASS Yogita Dental College and Hospital, Maharashtra University of health Sciences, Nasik, India.
4. Shivam Bhan, B.Tech Biotechnology, Amity University, Noida, UP, India.

59. Molecular modeling study of derivatives of dutasteride and Human Steroid 5β-Reductase (AKR1D1) | Discovery of new drugs for prostate cancer

1. Chhavi Rai, BDG LifeSciences, India.
2. Vinay Kumar, BDG LifeSciences, India
3. Dipjyoti Dey, Master of Science Applied Microbiology, Vellore Institute of Technology (VIT) University, Vellore, India.
4. Mehuli Mishra, B.Sc, Department of Biotechnology, Jyoti Nivas College, Bengaluru, India
5. Vidushi Aggarwal, B.Sc, Department of Biotechnology, Jyoti Nivas College, Bengaluru, India.
6. Disha Mitra, Biophysics, Molecular Biology and Bioinformatics, Rajabazar Science College, Calcutta University, India.
7. Suparna Maji, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India
8. Soumyadipta Das, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India
9. Suman Nayek, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India.
10. Subarna Chakraborty, B. Tech Genetic Engineering, SRM Institute of Science and Technology, India.

57. Molecular modeling study of α-glucosidase Inhibitors (AGIs) | Discovery of new anti-diabetic drugs by controlling postprandial hyperglycemia

1. Dr Minakshi Garg PhD, Assistant Professor in Biotechnology, University Institute of Engineering and Technology, Panjab University Chandigarh, India
2. M. Raghanivedha, Master of science in Biotechnology, Seattle, Washington, United States of America.
3. Shreya Mondal, B. Tech (Biotechnology), Amity University, Noida, India.
4. H. Vijayasri, B.Sc. (Hons) Biomedical Sciences at Sri Ramachandra Institute of Higher Education and Research (DU) Porur, Chennai.
5. Nikita Yadav, BS-MS Integrated Course, Indian Institute of Science Education and Research, Mohali, India
6. Sucharita Ghosh, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India.

56. Discovery of new ligands for PPAR Gamma responsible for Diabetes Type 2: A Virtual Screening, Docking & ADMET Study.

1. Bharti Mittal, PhD, Senior Scientist, Operations, MedGenome Labs Pvt Ltd, Bangalore, India.
2. Vivek Srivastava, Ph.D., Assistant Professor(Biochemistry), School of Basic Sciences and Research, Sharda University, Greater Noida, UP
3. Maitili Varma, Advanced Proficiency course in Genetic engineering, Genohelix Biolabs, Jain Group of Institutions, India.
4. Priyadarshini Sharma, B. Tech, Amity Institute of Biotechnology, Amity University, Noida, India.
5. Harshita Agarwal, B. Sc, Amity Institute of Biotechnology, Amity University, Noida , India.
6. Gupta Radha Devi Shivprakash, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India
7. Raisa Dabhilkar, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India.

53. Molecular Modelling study of phytoconstituents from medicinal plants of India | Discovery of natural anti-tubercular agents

1. Taiba Hamed Youssef Gamal El Din, Master in Biotechnology & Life Science, Bani Sueif University, Bani Sueif, Egypt.
2. Syeda Birjees Misbah, M.Sc., Biochemistry, REVA University, Bangalore, India.
3. Aindrila Pal, B. Tech, Amity Institute of Biotechnology, Amity University, Noida, India.
4. Preeti, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
5. Ngoc Pham, The Applied Chemistry Department of the International University, Ho Chi Minh, Vietnam.
6. Moumita Ganguly, Research Associate, IIT Mandi, India.
7. Deeksha Gairola, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
8. Ketaki Ghatole, B.E. Biotechnology, MS Ramaiah Institute of Technology, Bengaluru, India.

49. Molecular Modeling study of Zika Virus | Virtual Screening, Protein Modeling, Docking, ADMET and MD Simulations Study

1. Dr. Alam El-Din, Hanaa Mahmoud, Virology and Immnunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
2. Manjisa Choudhury, VIT University, Vellore, India.
3. Nada Gamal Ibrahim El-Dawy, Faculty of Biotechnology, October University for Modern Sciences and Arts, Egypt (MSA University).

39. Study of derivatives of Chalcones as new Tyrosinase inhibitors: A Molecular Docking, ADME & Tox Study

1. Adwaita Das, Department of Botany, The University of Burdwan, Burdwan, West Bengal, India
2. Shreya John MSc Bioinformatics, St. Aloysius Institute of Management and Technology, Mangalore University.
3. Lalit R. Samant, Project Assistant, Haffkine Institute for Training Research and Testing, India.
4. K.C. Haritah Yadav, M. Sc (Medical Pharmacology) from Kamineni Institute of Medical Sciences, Narkrtpally, Nalgonda, Andhra Pradesh.
5. Dr. N. Hari, School of Chemical & Biotechnology, SASTRA University, Thanjavur, Tamil Nadu.
6. Dr(Mrs) Jhaumeer Laulloo Sabina, University of Mauritius, Reduit, Mauritius.

34. Study of extracts of Veratrum Dahuricum as potential Anti-tumor molecules: Molecular Docking & Modeling study with Farnesyl Pyrophosphate Synthase (FFPS)

1. Gomathi Rajendran, ITC Zenith (M) Sdn. Bhd. (Conformity Assessment Body), Malaysia.
2. Seetha Harilal, Department of Pharmacology, Nehru College of Pharmacy, Kerala University of Health Sciences, Thrissur, Kerala, India.
3. Akshya Kumar Mailapali, I. M.Sc Bioinformatics , B.J.B. Autonomous College, Utkal University, Bhubaneshwar, India.
4. Tanya Munjal, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
5. Sambit Kumar Roy, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
6. Lucky Gupta, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
7. Gaurav Dutt, School of Basic and Applied Science, Dayananda Sagar University, Bangalore, India.